PCRX Earnings
Latest Revenue192.4M
Latest Net Income4.7M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.12 | 192.4M | 4.7M | +6.2% | +209.1% |
| Q1 2026 | $0.07 | 177.4M | 2.9M | +5.0% | -30.0% |
| Q4 2025 | $0.04 | 196.9M | 1.6M | +5.1% | -88.6% |
| Q3 2025 | $0.12 | 179.5M | 5.4M | +6.5% | +103.9% |
| Q2 2025 | -$0.11 | 181.1M | -4847000 | +1.7% | -126.8% |
| Q1 2025 | $0.10 | 168.9M | 4.8M | +1.1% | -47.4% |
| Q4 2024 | $0.35 | 187.3M | 16.0M | +3.3% | -35.2% |
| Q3 2024 | -$3.11 | 168.6M | -143466000 | +2.8% | -1,452.2% |
| Q2 2024 | $0.41 | 178.0M | 18.9M | — | — |
| Q1 2024 | $0.19 | 167.1M | 9.0M | — | — |
| Q4 2023 | $0.54 | 181.2M | 24.9M | — | — |
| Q3 2023 | $0.23 | 163.9M | 10.9M | — | — |
Pacira BioSciences (PCRX) — Earnings